Sage Therapeutics Inc
(FRA:SG7)
€
5.452
0.102 (1.91%)
Market Cap: 325.18 Mil
Enterprise Value: -211.07 Mil
PE Ratio: 0
PB Ratio: 0.61
GF Score: 49/100 SAGE Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 18, 2021 / 12:35PM GMT
Release Date Price:
€60.28
(-0.23%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Good morning, everyone. I'm Brian Abrahams, senior biotech analyst at RBC Capital Markets. Our next presenting company is Sage, featuring their CEO, Barry Greene. Barry, thanks so much for joining us.
Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director
Brian, thanks for having us, and I'd like to thank RBC for organizing this today.
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Our pleasure.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
So maybe let's kick things off on the most imminent data catalysts coming up, the WATERFALL data for zuranolone in major depressive disorder. Can you maybe start by talking about your latest views on how some of the adjustments and changes that you made in things like dosing, inclusion criteria and conduct
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot